Femasys

Femasys, Inc. operates as a medical device company that focuses on women's healthcare. Its products include FemVue Saline-Air Device, which creates and delivers an alternating pattern of saline and air as a continuous stream, and enables physicians to assess their patients fallopian tubes, and FemChec Pressure Management Device, which limits the maximum applied pressure while performing hysterosalpingogram. The firm offers FemCerv, an endocervical curettage device to collect a non-contaminated tissue sample for cervical cancer screening. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Femasys Inc. (FEMY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.26 per share a year ago.

Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates

Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment

Femasys Announces Infertility Clinic Customers from Coast to Coast

Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society's (CFAS) 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26.

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.

Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI

ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. The fireside chat will be hosted by Emily Bodnar, Life Sciences Analyst. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces that it has received CE mark certification and product approval from Health Canada, the Public Health Agency of Canada, for its compact, eco-friendly FemVue® MINI for fallopian tube assessment.

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

The Congresswoman representing Georgia's 7th district in the U.S. House of Representatives toured Femasys' facilities to gain a better understanding of our advancements for women's reproductive health The Congresswoman representing Georgia's 7th district in the U.S. House of Representatives toured Femasys' facilities to gain a better understanding of our advancements for women's reproductive health

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Femasys Inc. (FEMY) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago.

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Company gained CE Mark approval for four of its women's health products and completed buildout of commercial team for its infertility portfolio Company gained CE Mark approval for four of its women's health products and completed buildout of commercial team for its infertility portfolio

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Leading women's reproductive health conference directly follows the company's EU CE Mark approval for four of its products Leading women's reproductive health conference directly follows the company's EU CE Mark approval for four of its products

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

Femasys Inc. (FEMY) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago.

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc ® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2024 and provides a corporate update.

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Femasys (FEMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know

ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces its CEO and Founder Kathy Lee-Sepsick has met with several members of Congress to discuss the current women's healthcare landscape. Further, Lee-Sepsick is raising awareness of Femasys and the status of its reproductive products in light of the recently announced women's health initiative from the White House. In mid-March President Biden released an executive order, which calls for a $200M investment in research for women's health and a coordinated approach from more than 20 federal government agencies in addition to the $100M investment announced in November 2023.

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET -- -- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET --

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI) rate --

News for Femasys Stock (FEMY)